Drug Profile

Research programme: TL1A modulators - PsiThera

Latest Information Update: 01 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Psivant Therapeutics
Developer PsiThera
Class Anti-inflammatories; Antirheumatics; Small molecules
Mechanism of Action Tumour necrosis factor ligand superfamily member 15 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Aug 2024 Early research in Inflammatory bowel diseases in USA (PO), before August 2024 (Psivant Therapeutics pipeline, August 2024)
08 Aug 2024 Early research in Rheumatic disorders in USA (PO), before August 2024 (Psivant Therapeutics pipeline, August 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com